Treat patients estimated to have a ≥7.5% 10-year risk of cardiovascular events as recommended in the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults (class I; level of evidence A).

In patients with nonvalvular atrial fibrillation (AF) and a CHA2DS2-VASc score of ≥2 and acceptably low risk of complications, anticoagulation with either warfarin (class I; level of evidence A), dabigatran, apixaban, or rivaroxaban (class I; level of evidence B) is recommended.

Use of aspirin for cardiovascular disease (CVD) prophylaxis is reasonable for people who have a 10-year risk of a cardiovascular event >10% (class IIa; level of evidence A).

Aspirin is not useful in preventing stroke in people at low risk (class III; level of evidence A).